AG
NKTR icon

Aperio Group’s Nektar Therapeutics NKTR Stock Holding History

Aperio Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.36M Buy
5,328
+208
+4% +$53.7K ﹤0.01% 1429
2020
Q3 		$1.27M Buy
5,120
+251
+5% +$78.9K ﹤0.01% 1327
2020
Q2 		$1.69M Buy
4,869
+909
+23% +$284K 0.01% 1181
2020
Q1 		$1.06M Buy
3,960
+955
+32% +$295K ﹤0.01% 1279
2019
Q4 		$973K Buy
3,005
+513
+21% +$149K ﹤0.01% 1449
2019
Q3 		$681K Sell
2,492
-446
-15% -$164K ﹤0.01% 1592
2019
Q2 		$1.57M Buy
2,938
+224
+8% +$112K 0.01% 1182
2019
Q1 		$1.37M Buy
2,714
+265
+11% +$157K 0.01% 1206
2018
Q4 		$1.21M Sell
2,449
-78
-3% -$47.1K 0.01% 1207
2018
Q3 		$2.31M Sell
2,527
-153
-6% -$131K 0.01% 992
2018
Q2 		$1.96M Sell
2,680
-919
-26% -$1.06M 0.01% 1038
2018
Q1 		$5.74M Buy
3,599
+277
+8% +$357K 0.03% 605
2017
Q4 		$2.98M Buy
3,322
+423
+15% +$250K 0.02% 842
2017
Q3 		$1.04M Buy
2,899
+9
+0.3% +$2.81K 0.01% 1238
2017
Q2 		$847K Buy
2,890
+286
+11% +$82.7K 0.01% 1327
2017
Q1 		$917K Buy
2,604
+117
+5% +$26.3K 0.01% 1213
2016
Q4 		$457K Sell
2,487
-283
-10% -$57.5K ﹤0.01% 1562
2016
Q3 		$714K Buy
2,770
+970
+54% +$250K 0.01% 1263
2016
Q2 		$384K Sell
1,800
-54
-3% -$12.1K ﹤0.01% 1533
2016
Q1 		$382K Sell
1,854
-106
-5% -$20.4K ﹤0.01% 1505
2015
Q4 		$495K Buy
1,960
+594
+43% +$122K ﹤0.01% 1342
2015
Q3 		$224K Buy
1,366
+433
+46% +$76.6K ﹤0.01% 1706
2015
Q2 		$175K Buy
+933
New +$161K ﹤0.01% 1892

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Aperio Group's NKTR Position: Q4 2020 in Review

Aperio Group increased its Nektar Therapeutics (NKTR) stake by 4.1% in Q4 2020, buying an estimated $53.7K and bringing the position to 5,328 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1429.

Aperio Group first reported a position in NKTR in Q2 2015 and has held it in 23 quarters since. The position peaked at $5.74M in Q1 2018. 246 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

  • Aperio Group held 5,328 shares of Nektar Therapeutics worth $1.36M as of Q4 2020.
  • Aperio Group bought 208 Nektar Therapeutics shares in Q4 2020, an estimated $53.7K.
  • Nektar Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1429 holding.
  • Aperio Group first reported a position in Nektar Therapeutics in Q2 2015 and has held it in 23 quarters since.
  • Aperio Group's Nektar Therapeutics position peaked at $5.74M in Q1 2018.
  • 246 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.